A phase II study evaluated the efficacy and safety of MLN0128 and the combination of MLN0128 plus Serabelisib versus Everolimus in the treatment of metastatic clear-cell renal cell carcinoma (mccRCC) patients who progressed on vascular endothelial growth factor (VEGF)-targeted therapy [266]. This evidence concerns the gene VEGFA and clear cell renal carcinoma.